Biomarkers for Glioma Treatment Response
- Technology Benefits
- High accuracyand specificityInexpensiveSimple toimplement
- Detailed Technology Description
- Method for predictingmalignant glioma patient response to chemotherapy and radiotherapy based onSTAT3 pathway signaling#therapeutics #biomarkers#biomedical #healthcare #diagnostictool
- *Abstract
-
Northwestern University researchers have developeda method for discriminating between glioma patients who will and will notrespond to chemo- and radiotherapy treatment. While many therapies for cancerexist, it has been well understood in the cancer research community that geneexpression between two patients with identical cancer classifications impactshow the two patients respond to therapy. This understanding has led cliniciansto try to tailor their therapeutic approaches to each patient, but this task ismade more difficult by the fact that genetic factors affecting therapy responseare not always known. The Horvath group at Northwestern University hasidentified a set of 5 genes from the STAT 3 pathway, whose expression can beused to predict how high-risk malignant glioma patients will respond totherapy. This innovative approach to glioma treatment is cost-effective andsimple to implement in treatment and clinical trial settings. In addition tohelping improve patient outcomes, this invention could make an impacton drug discovery and pharmacogenomic studies as well.
- *Inventors
- Robert TellCurt Horvath*
- *Publications
- Tell RW, Horvath CM (2014) Bioinformaticanalysis reveals a pattern of STAT3-associated gene expression to basal-likebreast cancers in human tumors, PNAS,111: 12787-92.
- Country/Region
- USA
